Site develops incidental findings report model

September 2011
Clinical Trials Administrator;Sep2011, Vol. 9 Issue 9, p106
The article reports a model developed at Mind Research Network (MRN) in Albuquerque, New Mexico, for reporting incidental findings to study subjects. The model mandates that confidentiality is protected, and the emotional impact of the findings on the subjects is taken into consideration in order to reduce anxiety. Included are comments from John P. Phillips, the network's medical director.


Related Articles

  • Reporting incidental findings: ethical & vital.  // IRB Advisor;Sep2011, Vol. 11 Issue 9, p88 

    The article discusses that research sites have an ethical responsibility when it comes to reporting incidental findings on research subjects. It reports that Mind Research Network (MRN) has developed and executed a process that contains a template for reporting incidental findings to subjects....

  • Consent forms for clinical trials are too aggressive. Wassersug, Richard J. // BMJ: British Medical Journal;8/17/2013, Vol. 347 Issue 7921, p23 

    The author focuses on the aspects of the languages used in informed consent forms in clinical trials. He mentions that the form should be in clear, plain English that could be understood by someone without a university degree. He further mentions that the unfriendly text from consent forms...

  • Evaluation of factors that motivate participants to consent for non-therapeutic trials in India. Doshi, Maulik Sumantbhai; Kulkarni, Shaunak P.; Ghia, Canna J.; Gogtay, Nithya J.; Thatte, Urmila Mukund // Journal of Medical Ethics;Jun2013, Vol. 39 Issue 6, p391 

    Background and rationale Several factors that motivate individuals to participate in non-therapeutic studies have been identified. This study was conducted as limited data is available regarding these motivations from developing countries. Methods This was a single-centre study conducted over 4...

  • Helping researchers with a tough topic.  // IRB Advisor;Jan2011, Vol. 11 Issue 1, p10 

    The article discusses Phase 1 recruitment for oncology studies. Phase 1 involves inviting participants who will risk side effects and likely never see benefits from therapy. This is a challenge for providing informed consent, since most patients have unrealistic hopes for the drug. Doctor...

  • Here are site source document sample IC items.  // Clinical Trials Administrator;Jul2011, Vol. 9 Issue 7, p79 

    The article offers information on source documentation checklists for site visits, screening visits, and other clinical research activities, created by UT Medical Group Inc. of Memphis, Tennessee. It explores a list of sample items included on the template for a screening visit, which includes...

  • Focus on QA results in better informed consent.  // Clinical Trials Administrator;Jun2011, Vol. 9 Issue 6, p63 

    The article discusses a quality assurance (QA) process implemented at the Vanderbilt University in Nashville, Tennessee to improve how research costs were explained to the participants in informed consent (IC) documents and to promote consistency across study documents. Key points of the QA...

  • percepção dos doentes incluídos em ensaios clínicos relativamente ao processo de consentimento informado. Rodrigues Francisco, Maria de Fátima // Onco.news;mar-jun2012, Issue 20, p41 

    Clinical trials are the source for the development of new treatment strategies. Informed consent is an ethical safeguard for clinical trials candidates, in that it recognizes the autonomy to make decisions and the right to adequate information. However you must ensure that the information...

  • LAWS RELATING TO INFORMED CONSENT IN CLINICAL TRIALS. Craig, Kathrine J. // Nursing Standard;8/21/2013, Vol. 27 Issue 51, p33 

    A letter to the editor is presented in response to an article by Andrew Pick et al. in the August 7, 2013 issue which was concerned with laws relating to informed consent in clinical research trials.

  • “It is not guaranteed that you will benefit”: True but misleading? Kim, Scott Y. H.; Wilson, Renee; De Vries, Raymond; Kim, H. Myra; Holloway, Robert G.; Kieburtz, Karl // Clinical Trials;Aug2015, Vol. 12 Issue 4, p424 

    Background: Participants of early-phase intervention trials for serious conditions provide high estimates of likelihood of benefit, even when informed consent forms do not promise such benefits. However, some technically correct, negatively stated benefits statements—such as “it is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics